Pharmacoeconomics, Epidemiology, Pharmaceutical Policy and Outcomes Research (PEPPOR) Program, Department of Pharmacy Practice and Administrative Sciences, College of Pharmacy, University of New Mexico, Albuquerque, NM, USA.
Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):327-42. doi: 10.1586/erp.13.26.
Prostate cancer is the most common non-skin cancer in American men, and prostate-specific antigen (PSA) testing is its common screening procedure. In May 2012, the US Preventive Services Task Force recommended against PSA-based screening. These recommendations contradict the current recommendations of other organizations such as the American Urological Association. The authors conducted a systematic review of PubMed, EMBASE and Cochrane to examine the published literature reporting the cost-effectiveness of PSA-based screening. The authors found ten studies each for US and non-US jurisdiction population. All reviewed studies concluded PSA-based screening to be cost effective in younger men (≤60 years of age) and at higher PSA levels (≥3 ng/ml). Further cost-effectiveness analyses reflecting latest clinical practice and current perspectives regarding adverse outcomes of potentially unnecessary treatment are required, especially from the US government perspective.
前列腺癌是美国男性最常见的非皮肤癌，前列腺特异性抗原（PSA）检测是其常见的筛查方法。2012 年 5 月，美国预防服务工作组建议不要进行基于 PSA 的筛查。这些建议与美国泌尿外科学会等其他组织的现行建议相矛盾。作者对 PubMed、EMBASE 和 Cochrane 进行了系统评价，以检查报告基于 PSA 的筛查成本效益的已发表文献。作者为美国和非美国司法管辖区的人群各找到了 10 项研究。所有审查过的研究都得出结论，在较年轻的男性（≤60 岁）和 PSA 水平较高（≥3ng/ml）的男性中，基于 PSA 的筛查具有成本效益。需要进一步进行成本效益分析，反映最新的临床实践和对潜在不必要治疗的不良后果的当前观点，特别是从美国政府的角度来看。
